Gilead Sciences, Inc. (GILD): Rumor News

GILD – The Evening Standard discusses market rumors that Gilead & GlaxoSmithKlein may be eyeing United Therapeutics.


Key Facts Surrounding This News Item


  • GILD had a POWR Rating of B (Buy) coming into today.
  • GILD was -0.70% below its 10-Day Moving Average coming into today.
  • GILD was 2.10% above its 20-Day Moving Average coming into today.
  • GILD was 7.60% above its 50-Day Moving Average coming into today.
  • GILD was 9.75% above its 100-Day Moving Average coming into today.
  • GILD was 6.91% above its 200-Day Moving Average coming into today.
  • GILD had returned +5.50% year-to-date leading up to today’s news, versus a +11.50% return from the benchmark S&P 500 during the same period.

More Info About Gilead Sciences, Inc. (GILD)


Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. View our full GILD ticker page with ratings, news, and more.

GILD at a Glance

GILD Current POWR Rating™
Overall POWR Rating™
GILD Current Price $79.95 1.50%
More GILD Ratings, Data, and News

GILD Price Reaction

The day of this event (Aug. 4, 2017)
GILD Closing Price$72.71 1.63%
GILD Volume15,054,350
55.02% from avg
Leading up to this event
GILD 1-mo returnN/A%
After this event
GILD 1-day return1.27%
GILD 3-day return0.64%
GILD 5-day return2.72%

GILD Price Chart



More Gilead Sciences, Inc. (GILD) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GILD News
Page generated in 1.0269 seconds.